Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Sobieszczyk, ME; Maaske, J; Falsey, AR; Sproule, S; Robb, ML; Frenck, RW; Tieu, HV; Mayer, KH; Corey, L; Neuzil, KM; Tong, T; Isaacs, MB; Janes, H; Bansal, H; Edwards, LM; Green, JA; Kelly, EJ; Shoemaker, K; Takas, T; White, T; Bhuyan, P; Villafana, T; Hirsch, I

Hirsch, I (通讯作者)，AstraZeneca, Biometr Vaccines & Immune Therapies, BioPharmaceut R&D, Acad House,132-136 Hills Rd, Cambridge CB2 8PA, England.

JOURNAL OF CLINICAL INVESTIGATION, 2022; 132 (18):

Abstract

BACKGROUND. We report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) from an ongoing phase 3 trial. METHODS. Adults at incr......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索